📊 BPTH Key Takeaways
Investment Thesis
Bio-Path Holdings is in critical financial distress with zero revenue, negative stockholders' equity of -$8.0M, and severe liquidity constraints (0.08x current ratio). The company is burning cash at -$1.6M annually with no operating income while carrying $8.7M in liabilities against only $690K in assets, indicating imminent solvency risk.
BPTH Strengths
- No long-term debt obligations reducing refinancing risk
- Minimal capital expenditure requirements suggesting asset-light operations
- EPS improvement of 87.7% YoY indicates reduced dilution rate
BPTH Risks
- Negative stockholders' equity of -$8.0M indicates balance sheet insolvency
- Zero revenue generation with -$8.3M operating loss signals complete operational failure
- Critical liquidity crisis with $0 cash and 0.08x current ratio threatening going concern status
- Negative free cash flow of -$1.6M draining remaining capital resources
- Total liabilities ($8.7M) exceed total assets ($690K) by 12.6x indicating balance sheet collapse
Key Metrics to Watch
- Cash runway and path to positive cash flow
- Revenue re-initiation and clinical trial progress
- Debt restructuring or capital raise announcements
- Stockholders' equity trajectory back to positive
- Monthly cash burn rate and operating expense reduction
BPTH Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BPTH Profitability Ratios
BPTH vs Healthcare Sector
How BIO-PATH HOLDINGS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BPTH Balance Sheet & Liquidity
BPTH 5-Year Financial Trend
5-Year Trend Summary: BIO-PATH HOLDINGS, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-33.63 indicates the company is currently unprofitable.
BPTH Growth Metrics (YoY)
BPTH Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2017 | N/A | -$1.6M | N/A |
| Q2 2017 | N/A | -$1.9M | N/A |
| Q1 2017 | N/A | -$397.0K | N/A |
| Q3 2016 | N/A | -$1.5M | N/A |
| Q2 2016 | N/A | -$1.1M | N/A |
| Q1 2016 | N/A | -$1.4M | N/A |
| Q3 2015 | N/A | -$1.1M | N/A |
| Q2 2015 | N/A | -$1.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BPTH Capital Allocation
BPTH SEC Filings
Access official SEC EDGAR filings for BIO-PATH HOLDINGS, INC. (CIK: 0001133818)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BPTH
What is the AI rating for BPTH?
BIO-PATH HOLDINGS, INC. (BPTH) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BPTH's key strengths?
No long-term debt obligations reducing refinancing risk. Minimal capital expenditure requirements suggesting asset-light operations.
What are the risks of investing in BPTH?
Negative stockholders' equity of -$8.0M indicates balance sheet insolvency. Zero revenue generation with -$8.3M operating loss signals complete operational failure.
What is BPTH's revenue and growth?
BIO-PATH HOLDINGS, INC. reported revenue of $0.0.
Does BPTH pay dividends?
BIO-PATH HOLDINGS, INC. does not currently pay dividends.
Where can I find BPTH SEC filings?
Official SEC filings for BIO-PATH HOLDINGS, INC. (CIK: 0001133818) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BPTH's EPS?
BIO-PATH HOLDINGS, INC. has a diluted EPS of $-1.07.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.